Vical Incorporated (NASDAQ:VICL) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 12, 2016
Zacks Investment Research has downgraded Vical Incorporated (NASDAQ:VICL) to Hold in a statement released on 10/12/2016.
On 09/21/2016, Zacks Investment Research released a statement for Vical Incorporated (NASDAQ:VICL) bumped up the target price from $0.00 to $3.50 that suggested an upside of 0.14%.
Boasting a price of $3.00, Vical Incorporated (NASDAQ:VICL) traded 0.27% higher on the day. With the last stock price close down -24.29% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Vical Incorporated has recorded a 50-day average of $3.48 and a two hundred day average of $3.99. Volume of trade was down over the average, with 6,338 shares of VICL changing hands under the typical 33,705
With a total market value of $0, Vical Incorporated has with a one year low of $2.80 and a one year high of $5.40 .
General Company Details For Vical Incorporated (NASDAQ:VICL)
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.